Security Snapshot

REGENXBIO Inc. - Common Stock (RGNX) Institutional Ownership

CUSIP: 75901B107

13F Institutional Holders and Ownership History from Q3 2015 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

172

Shares (Excl. Options)

41,068,451

Price

$14.40

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.

Create free account to save this page Review latest holder period
Type / Class
Equity / Common Stock
Symbol
RGNX on Nasdaq
Shares outstanding
50,868,756
Price per share
$8.38
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
41,068,451
Total reported value
$591,295,423
% of total 13F portfolios
0%
Share change
-634,347
Value change
-$5,673,459
Number of holders
172
Price from insider filings
$8.38
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • RGNX - REGENXBIO Inc. - Common Stock is tracked under CUSIP 75901B107.
  • 172 institutions reported positions in Q4 2025.
  • 5 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 172 to 12 between Q4 2025 and Q1 2026.
  • Reported value moved from $591,295,423 to $745,652.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 172 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 75901B107?
CUSIP 75901B107 identifies RGNX - REGENXBIO Inc. - Common Stock in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of REGENXBIO Inc. - Common Stock (RGNX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Redmile Group, LLC 9.9% $43,942,300 5,062,477 Redmile Group, LLC 30 Jun 2025
JPMORGAN CHASE & CO 7.4% $34,806,291 3,698,862 JPMORGAN CHASE & CO. 31 Dec 2024
BlackRock, Inc. 7.3% -34% $34,616,925 -$16,819,095 3,678,738 -33% BlackRock, Inc. 31 Mar 2025
STATE STREET CORP 4.4% $20,568,858 2,185,851 STATE STREET CORPORATION 31 Dec 2024
BlackRock Portfolio Management LLC 4.1% -35% $30,032,914 -$15,091,042 2,085,619 -33% BlackRock Portfolio Management LLC 31 Dec 2025

As of 31 Dec 2025, 172 institutional investors reported holding 41,068,451 shares of REGENXBIO Inc. - Common Stock (RGNX). This represents 81% of the company’s total 50,868,756 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of REGENXBIO Inc. - Common Stock (RGNX) together control 68% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 11% 5,756,811 -9.6% 0% $82,898,078
Redmile Group, LLC 8.6% 4,368,804 -6.9% 4.6% $62,910,778
JPMORGAN CHASE & CO 7% 3,553,502 -12% 0% $51,170,429
VANGUARD GROUP INC 6.6% 3,374,140 +1.1% 0% $48,587,616
STATE STREET CORP 4.5% 2,286,736 +15% 0% $32,928,998
MORGAN STANLEY 4% 2,014,787 +18% 0% $29,012,933
GOLDMAN SACHS GROUP INC 3.5% 1,785,437 -3.6% 0% $25,710,293
AQR CAPITAL MANAGEMENT LLC 2.7% 1,361,962 +5.6% 0.01% $19,612,253
Integral Health Asset Management, LLC 2.4% 1,200,000 +9.1% 0.88% $17,280,000
Assenagon Asset Management S.A. 2.3% 1,160,380 +64% 0.03% $16,709,472
GEODE CAPITAL MANAGEMENT, LLC 2.3% 1,145,206 +1.7% 0% $16,495,225
22NW, LP 1.8% 923,679 0% 10% $13,300,978
DIMENSIONAL FUND ADVISORS LP 1.8% 903,851 -18% 0% $13,014,235
Nuveen, LLC 1.3% 658,510 +19% 0% $9,482,544
Pale Fire Capital SE 0.98% 499,526 +95% 0.93% $7,193,174
Qube Research & Technologies Ltd 0.87% 442,690 +55% 0.01% $6,374,736
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.77% 391,461 -0.13% 0% $5,637,038
ACADIAN ASSET MANAGEMENT LLC 0.74% 375,399 -5.9% 0.01% $5,404,000
NORTHERN TRUST CORP 0.73% 373,689 -6.8% 0% $5,381,121
STIFEL FINANCIAL CORP 0.66% 335,046 +4.6% 0% $4,824,676
RENAISSANCE TECHNOLOGIES LLC 0.65% 333,086 +7.6% 0.01% $4,796,438
BANK OF AMERICA CORP /DE/ 0.59% 300,609 -28% 0% $4,328,769
HRT FINANCIAL LP 0.59% 299,915 +74% 0.01% $4,318,000
Voss Capital, LP 0.58% 295,000 -41% 0.23% $4,248,000
GSK plc 0.53% 271,456 0% 0.49% $3,908,966

Institutional Holders of REGENXBIO Inc. - Common Stock (RGNX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 88,211 $745,652 -$172,963 $8.38 12
2025 Q4 41,068,451 $591,295,423 -$5,673,459 $14.40 172
2025 Q3 41,358,721 $399,176,079 -$3,663,002 $9.65 165
2025 Q2 42,035,725 $345,140,942 +$5,513,913 $8.21 159
2025 Q1 41,667,225 $297,962,085 -$1,501,158 $7.15 163
2024 Q4 42,074,510 $325,173,475 -$15,537,348 $7.73 175
2024 Q3 43,665,569 $458,056,433 -$8,522,130 $10.49 184
2024 Q2 43,782,930 $512,285,979 +$5,420,902 $11.70 180
2024 Q1 42,534,646 $895,831,731 +$95,824,018 $21.07 185
2023 Q4 38,123,027 $684,323,807 +$18,843,309 $17.95 167
2023 Q3 37,072,487 $610,280,035 -$2,249,035 $16.46 157
2023 Q2 37,122,782 $742,048,193 +$3,963,188 $19.99 165
2023 Q1 37,009,156 $699,776,275 +$18,824,498 $18.91 170
2022 Q4 35,702,552 $809,736,875 +$5,376,487 $22.68 180
2022 Q3 35,093,974 $927,284,018 -$30,479,732 $26.43 173
2022 Q2 36,159,183 $893,093,296 +$28,890,952 $24.70 157
2022 Q1 34,902,249 $1,157,712,999 -$21,017,474 $33.19 181
2021 Q4 35,507,306 $1,160,896,124 +$58,351,051 $32.70 168
2021 Q3 33,398,271 $1,400,353,918 -$3,046,167 $41.92 177
2021 Q2 33,460,640 $1,299,751,931 +$26,836,789 $38.85 168
2021 Q1 32,853,108 $1,120,584,466 +$187,839,315 $34.11 178
2020 Q4 27,329,284 $1,239,697,831 -$41,654,835 $45.36 182
2020 Q3 28,512,126 $785,403,793 -$29,743,448 $27.52 162
2020 Q2 29,376,827 $1,082,072,585 +$20,048,711 $36.83 174
2020 Q1 28,922,545 $936,893,202 -$29,109,226 $32.38 160
2019 Q4 29,584,479 $1,212,076,877 -$13,179,927 $40.97 178
2019 Q3 29,248,667 $1,041,238,768 -$21,895,746 $35.60 165
2019 Q2 29,447,574 $1,510,592,208 -$22,838,253 $51.37 184
2019 Q1 30,143,203 $1,727,382,727 +$15,646,108 $57.31 206
2018 Q4 29,941,433 $1,255,681,603 +$31,694,613 $41.95 178
2018 Q3 28,543,303 $2,154,975,590 +$194,166,110 $75.50 198
2018 Q2 26,028,733 $1,867,750,691 +$332,228,528 $71.75 174
2018 Q1 22,371,972 $667,791,727 +$29,287,426 $29.85 118
2017 Q4 21,584,761 $717,686,392 +$5,112,723 $33.25 106
2017 Q3 21,399,716 $704,035,906 -$14,361,368 $32.95 87
2017 Q2 22,655,785 $447,763,347 +$37,345,656 $19.75 86
2017 Q1 20,796,965 $401,380,019 +$94,928,884 $19.30 86
2016 Q4 18,300,126 $339,456,250 +$28,424,124 $18.55 77
2016 Q3 16,939,017 $237,123,842 +$3,104,010 $14.01 71
2016 Q2 17,911,156 $143,725,600 +$9,894,905 $8.00 67
2016 Q1 16,627,713 $179,564,518 +$4,021,922 $10.80 62
2015 Q4 15,040,714 $247,165,923 -$9,897,144 $16.60 65
2015 Q3 14,305,786 $310,215,000 +$310,214,985 $22.03 47